NDA 020124 · US Army
Diazepam
Diazepam · Injection · Benzodiazepine
DiscontinuedLast checked: Nov 19, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Dec 5, 1990
Approved uses
1
Original approval plus efficacy supplements
Registered trials
118
16 Phase 3, 6 recruiting
FAERS reports
90,056
76,641 serious, 20,859 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation (see WARNINGS and PRECAUTIONS ). The use of benzodiazepines, including Diazepam injection, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing...
What it is approved for
From the label in effect Dec 18, 2023.
INDICATIONS Diazepam is indicated for the management of anxiety disorders for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Note: Because the autoinjector provides a minimum dose of 10 mg diazepam, it should not be used to treat individuals with mild and moderate degrees of anxiety and anxiety related disorders that would ordinarily be managed with intramuscular doses of less than 10 mg. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient's recall of the procedures (See WARNINGS ). Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff man syndrome; and tetanus. Diazepam injection is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is useful premedication for relief of anxiety and tension in patients who are to undergo surgical procedures.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 5, 1990 Original approval · Type 3 - New Dosage Form
1 products under this application
- DIAZEPAM · DIAZEPAM 5MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Diazepam" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of Intravenous Diazepam Given at 2 Different Doses Compared to Placebo in Acute Peripheral VertigoPivotal-lookingStatus unknown
University of MonastirAcademic, hospital or other
NCT06293989 · 1,000 participants (planned) · Start May 1, 2024 · Primary completion Dec 30, 2025
Drug: Diazepam 5mg; Diazepam 10 mg and 1 more · For: Vertigo, Peripheral
- Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in AsthmaPivotal-lookingCompleted
Oriel TherapeuticsIndustry
NCT02260492 · 879 participants · Start Sep 2014 · Primary completion May 2015
Drug: OT329 (combination of fluticasone propionate and salmeterol xinafoate); Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate) and 1 more · For: Asthma
Sites: Goodyear, Arizona; Tempe, Arizona; Anaheim, California · 47 sites in all
- Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)Pivotal-lookingCompleted
Avanti AnesthesiaAcademic, hospital or other
NCT03653520 · 651 participants · Start Jun 28, 2017 · Primary completion Nov 2, 2017
Drug: Diazepam; Tramadol and 2 more · For: Cataract
Sites: Houston, Texas
- Therapeutic Drug Monitoring of Anxiolytics in ChildrenStatus unknown
Wei ZhaoAcademic, hospital or other
NCT03960671 · 500 participants (planned) · Start Aug 1, 2018 · Primary completion Dec 31, 2022
Drug: Midazolam/diazepam/propofol · For: Anxiolytics
Sites: Ji'nan, China
- Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)Pivotal-lookingCompleted
McMaster UniversityAcademic, hospital or other
NCT03053869 · 480 participants · Start Apr 1, 2017 · Primary completion Sep 30, 2018
Drug: Benzodiazepine - limited use strategy; Benzodiazepine - Ad libitum strategy · For: Post-operative Delirium
Sites: Winnipeg, Canada; Hamilton, Canada
- Pharmacovigilance in Gerontopsychiatric PatientsPivotal-lookingTerminated
Hannover Medical SchoolAcademic, hospital or other
NCT02374567 · 407 participants · Start Jan 2015 · Primary completion Jun 28, 2017
Drug: Phenobarbital; Phenytoin and 95 more · For: Dementia; Depression; Schizophrenia and 2 more
Sites: Augsburg, Germany; Berlin, Germany; Hanover, Germany · 5 sites in all
- Diazepam at the Active Phase of LaborPivotal-lookingStatus unknown
Navy General Hospital, BeijingAcademic, hospital or other
NCT02232035 · 400 participants (planned) · Start Sep 2014 · Primary completion Sep 2015
Drug: normal saline/diazepam at the active phase of labor · For: Pain; Prolonged Labour
Sites: Beijing, China
- Intranasal Midazolam Versus Rectal Diazepam for Treatment of SeizuresPivotal-lookingCompleted
University of UtahAcademic, hospital or other
NCT00326612 · 358 participants · Start Jun 2006 · Primary completion Dec 2008
Drug: Midazolam; Diazepam · For: Seizures
Sites: Salt Lake City, Utah
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxicity to various agents9,224
- drug abuse6,198
- drug ineffective5,045
- nausea4,204
- drug interaction3,886
- completed suicide3,880
- fatigue3,807
- somnolence3,636
- off label use3,550
- anxiety3,387
- death3,387
- headache3,270
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,140 |
| 2005 | 1,344 |
| 2006 | 1,170 |
| 2007 | 1,233 |
| 2008 | 1,797 |
| 2009 | 1,793 |
| 2010 | 2,345 |
| 2011 | 2,776 |
| 2012 | 3,252 |
| 2013 | 3,740 |
| 2014 | 3,767 |
| 2015 | 4,658 |
| 2016 | 5,306 |
| 2017 | 5,529 |
| 2018 | 6,524 |
| 2019 | 7,145 |
| 2020 | 6,726 |
| 2021 | 5,695 |
| 2022 | 4,983 |
| 2023 | 4,864 |
| 2024 | 5,151 |
| 2025 | 5,144 |
| 2026 | 3,963 |
Recalls
1 FDA enforcement reports for this application.
Jun 6, 2012 · Class II · Terminated
Impurities/Degradation Products: High Out of Specification levels for carbostyril, a known degradation product of diazepam.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Diazepam* (Diazepam)
2024 spending
$18.9M
Beneficiaries
928,913
2,984,541 claims
Per beneficiary
$20
$0.94 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $26,863,476 |
| 2021 | $25,150,473 |
| 2022 | $22,908,990 |
| 2023 | $22,543,778 |
| 2024 | $18,938,266 |
Part B: Diazepam (Diazepam) · HCPCS J3360
2024 spending
$20K
Beneficiaries
1,310
2,217 claims
Per beneficiary
$15
2024 ASP limit $5.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $34,215 |
| 2021 | $29,475 |
| 2022 | $23,863 |
| 2023 | $20,945 |
| 2024 | $20,065 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Diazepam modulates hippocampal CA1 functional connectivity in people at clinical high-risk for psychosis.
Livingston NR, Kiemes A, O'Daly O, et al. · Psychol Med 2025 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Anticonvulsant therapy for status epilepticus.
Prasad K, Al-Roomi K, Krishnan PR, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Is diazepam an antidepressant?
Tiller JW, Schweitzer I, Maguire KP, et al. · Br J Psychiatry 1989 · Clinical Trial, Comparative Study
- Premedication for fibreoptic bronchoscopy.
Rees PJ, Hay JG, Webb JR · Thorax 1983 · Clinical Trial, Comparative Study
- Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.
Appleton R, Macleod S, Martland T · Cochrane Database Syst Rev 2008 · Meta-Analysis, Systematic Review
- Intermittent oral diazepam prophylaxis in febrile convulsions: its effectiveness for febrile seizure recurrence.
Verrotti A, Latini G, di Corcia G, et al. · Eur J Paediatr Neurol 2004 · Clinical Trial, Randomized Controlled Trial
Sponsor: US Army
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.